{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:29:07Z","timestamp":1786325347984,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117075","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:20:36Z","timestamp":1782735636000},"page":"117075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["ANXA2+\/TNR\u2212 glioblastoma subpopulation drives tumor progression through via Src-STAT3 axis and neutrophil remodeling"],"prefix":"10.1016","volume":"186","author":[{"given":"Jiaoming","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjian","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117075_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12943-022-01513-z","article-title":"Glioma targeted therapy: insight into future of molecular approaches","volume":"21","author":"Yang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117075_bb0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2159-8290.CD-20-1474","article-title":"Diffuse glioma heterogeneity and its therapeutic implications","volume":"11","author":"Nicholson","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117075_bb0015","doi-asserted-by":"crossref","unstructured":"Li T, Li J, Chen Z, Zhang S, Li S, Wageh S, Al-Hartomy OA, Al-Sehemi AG, Xie Z, Kankala RK, et al. Glioma diagnosis and therapy: current challenges and nanomaterial-based solutions. J. Control. Release 2022; 352:338\u201370.","DOI":"10.1016\/j.jconrel.2022.09.065"},{"key":"10.1016\/j.intimp.2026.117075_bb0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","article-title":"Emerging therapies for glioblastoma: current state and future directions","volume":"41","author":"Rong","year":"2022","journal-title":"Journal of experimental & clinical cancer research\u202f: CR"},{"key":"10.1016\/j.intimp.2026.117075_bb0025","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3389\/fimmu.2020.01402","article-title":"Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma","volume":"11","author":"DeCordova","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117075_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.995498","article-title":"Exploring glioblastoma stem cell heterogeneity: immune microenvironment modulation and therapeutic opportunities","volume":"12","author":"Johnson","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117075_bb0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ccell.2020.04.001","article-title":"The glioma stem cell model in the era of single-cell genomics","volume":"37","author":"Suv\u00e0","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2026.117075_bb0040","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7150\/thno.41692","article-title":"Glioma stem cells and their roles within the hypoxic tumor microenvironment","volume":"11","author":"Boyd","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.117075_bb0045","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.7150\/jca.55173","article-title":"Advances in cancer treatment: a new therapeutic target, annexin A2","volume":"12","author":"Li","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.intimp.2026.117075_bb0050","doi-asserted-by":"crossref","unstructured":"Mahdi AF, Malacrida B, Nolan J, McCumiskey ME, Merrigan AB, Lal A, Tormey S, Lowery AJ, McGourty K, Kiely PA. Expression of annexin A2 promotes cancer progression in estrogen receptor negative breast cancers. Cells 2020; 9.","DOI":"10.3390\/cells9071582"},{"key":"10.1016\/j.intimp.2026.117075_bb0055","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ijc.34048","article-title":"Annexin A2: the diversity of pathological effects in tumorigenesis and immune response","volume":"151","author":"Huang","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2026.117075_bb0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s12032-025-02799-x","article-title":"Annexin A2: regulating glioma\u2019s fate and a potential therapeutic target","volume":"42","author":"Liu","year":"2025","journal-title":"Medical oncology (Northwood, London, England)"},{"key":"10.1016\/j.intimp.2026.117075_bb0065","doi-asserted-by":"crossref","unstructured":"Uchihara T, Miyake K, Yonemura A, Komohara Y, Itoyama R, Koiwa M, Yasuda T, Arima K, Harada K, Eto K, et al. Extracellular vesicles from cancer-associated fibroblasts containing annexin A6 induces FAK-YAP activation by stabilizing \u03b21 integrin, enhancing drug resistance. Cancer Res. 2020; 80:3222\u201335.","DOI":"10.1158\/0008-5472.CAN-19-3803"},{"key":"10.1016\/j.intimp.2026.117075_bb0070","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/02713683.2021.2018467","article-title":"Annexin A2 promotes development of retinal neovascularization through PI3K\/ AKT signaling pathway","volume":"47","author":"Li","year":"2022","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.intimp.2026.117075_bb0075","article-title":"Early days of tenascin-R research: two approaches discovered and shed light on tenascin-R","volume":"11","author":"Rathjen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117075_bb0080","doi-asserted-by":"crossref","unstructured":"Dankovich TM, Kaushik R, Olsthoorn LHM, Petersen GC, Giro PE, Kluever V, Ag\u00fci-Gonzalez P, Grewe K, Bao G, Beuermann S, et al. Extracellular matrix remodeling through endocytosis and resurfacing of tenascin-R. Nat. Commun. 2021; 12:7129.","DOI":"10.1038\/s41467-021-27462-7"},{"key":"10.1016\/j.intimp.2026.117075_bb0085","doi-asserted-by":"crossref","first-page":"1554312","DOI":"10.3389\/fcell.2025.1554312","article-title":"The role of tenascin-C in tumor microenvironments and its potential as a therapeutic target","volume":"13","author":"Wang","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2026.117075_bb0090","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.260244","article-title":"Advances on the roles of tenascin-C in cancer","volume":"135","author":"Yilmaz","year":"2022","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.intimp.2026.117075_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbplus.2020.100021","article-title":"Loss of tenascin-X expression during tumor progression: a new pan-cancer marker","volume":"6-7","author":"Liot","year":"2020","journal-title":"Matrix biology plus"},{"key":"10.1016\/j.intimp.2026.117075_bb0100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12885-022-10492-9","article-title":"The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification)","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2026.117075_bb0105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163451","article-title":"Monocyte-neutrophil entanglement in glioblastoma","volume":"133","author":"Friedmann-Morvinski","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.117075_bb0110","doi-asserted-by":"crossref","unstructured":"Obeagu EI, Ezeala CC. Neutrophils as key regulators of tumor microenvironment in breast cancer: a focus on N1 and N2 polarization. Annals of medicine and surgery (2012) 2025; 87:3509\u201322.","DOI":"10.1097\/MS9.0000000000003269"},{"key":"10.1016\/j.intimp.2026.117075_bb0115","doi-asserted-by":"crossref","unstructured":"Chen N, Alieva M, van der Most T, Klazen JAZ, Vollmann-Zwerenz A, Hau P, Vrisekoop N. Neutrophils promote glioblastoma tumor cell migration after biopsy. Cells 2022; 11.","DOI":"10.3390\/cells11142196"},{"key":"10.1016\/j.intimp.2026.117075_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155828","article-title":"Interleukin-8: An evolving chemokine","volume":"153","author":"Matsushima","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2026.117075_bb0125","doi-asserted-by":"crossref","unstructured":"Zhang X, Huang X, Zhang X, Lai L, Zhu B, Lin P, Kang Z, Yin D, Tian D, Chen Z, et al. The miR-941\/FOXN4\/TGF-\u03b2 feedback loop induces N2 polarization of neutrophils and enhances tumor progression of lung adenocarcinoma. Front. Immunol. 2025; 16:1561081.","DOI":"10.3389\/fimmu.2025.1561081"},{"key":"10.1016\/j.intimp.2026.117075_bb0130","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.biocel.2012.05.009","article-title":"Tenascin-R: role in the central nervous system","volume":"44","author":"Anlar","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.intimp.2026.117075_bb0135","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejmech.2019.04.024","article-title":"Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors","volume":"174","author":"Cai","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.intimp.2026.117075_bb0140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2026.117075_bb0145","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.117075_bb0150","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","article-title":"Glioblastoma heterogeneity at single cell resolution","volume":"42","author":"Eisenbarth","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.117075_bb0155","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noab269","article-title":"Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma","volume":"24","author":"Yabo","year":"2022","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.intimp.2026.117075_bb0160","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.18632\/oncotarget.23627","article-title":"Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer","volume":"9","author":"Gibbs","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.117075_bb0165","doi-asserted-by":"crossref","first-page":"106405","DOI":"10.18632\/oncotarget.22433","article-title":"Stromal annexin A2 expression is predictive of decreased survival in pancreatic cancer","volume":"8","author":"Murphy","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.117075_bb0170","doi-asserted-by":"crossref","first-page":"20839","DOI":"10.1038\/s41598-021-00366-8","article-title":"ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppression","volume":"11","author":"Ma","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.117075_bb0175","doi-asserted-by":"crossref","unstructured":"Massara M, Persico P, Bonavita O, Mollica Poeta V, Locati M, Simonelli M, Bonecchi R. Neutrophils in gliomas. Front. Immunol. 2017; 8:1349.","DOI":"10.3389\/fimmu.2017.01349"},{"key":"10.1016\/j.intimp.2026.117075_bb0180","article-title":"Engineering and targeting neutrophils for Cancer therapy","volume":"36","author":"Zhang","year":"2024","journal-title":"Advanced materials (Deerfield Beach, Fla)"},{"key":"10.1016\/j.intimp.2026.117075_bb0185","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/imr.12444","article-title":"Neutrophils in cancer","volume":"273","author":"Treffers","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2026.117075_bb0190","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11060-009-9916-2","article-title":"Improving the prognosis for patients with glioblastoma: the rationale for targeting Src","volume":"95","author":"de Groot","year":"2009","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.intimp.2026.117075_bb0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12964-020-0527-z","article-title":"Role of STAT3 signaling pathway in breast cancer","volume":"18","author":"Ma","year":"2020","journal-title":"Cell Commun. Signaling\u202f: CCS"},{"key":"10.1016\/j.intimp.2026.117075_bb0200","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in Cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117075_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218303","article-title":"Treg-driven magnetic resonance radiomics in glioblastoma: a multicenter and cross-species model for prognostic biomarker discovery","volume":"642","author":"Wang","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.117075_bb0210","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/brain\/awab340","article-title":"An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas","volume":"145","author":"Li","year":"2022","journal-title":"Brain\u202f: J. Neurol."},{"key":"10.1016\/j.intimp.2026.117075_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216380","article-title":"Noninvasive radiomics model reveals macrophage infiltration in glioma","volume":"573","author":"Fan","year":"2023","journal-title":"Cancer Lett."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926009215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926009215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:48:34Z","timestamp":1786322914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926009215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"alternative-id":["S1567576926009215"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117075","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ANXA2+\/TNR\u2212 glioblastoma subpopulation drives tumor progression through via Src-STAT3 axis and neutrophil remodeling","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117075"}}